Fluocinolone Ophthalmic Dosage

Medically reviewed by Drugs.com. Last updated on Oct 7, 2024.

Usual Adult Dose for Uveitis

1 implant, containing 1 tablet of 0.59 mg of fluocinolone acetonide, to be surgically implanted into the posterior segment of the affected eye through a pars plana incision

Comments:

• Following depletion of this drug as evidenced by recurrence of uveitis, the implant may be replaced.
• Caution should be used in handling the implant to avoid damage, which may result in an increased rate of drug release from the implant.
• Care should be taken during implantation and explantation to avoid sheer forces on the implant that could disengage the silicone cup reservoir from the suture tab.
• Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure.
• The implant should not be resterilized by any method.

Use: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye

Usual Adult Dose for Macular Edema

1 implant, containing 0.19 mg of fluocinolone acetonide, to be surgically implanted inferior to the optic disc and posterior to the equator of the eye

Comments:

• For ophthalmic intravitreal injection.
• Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure. Consult the manufacturer product information for proper handling.
• Patients should be monitored for elevation in intraocular pressure and for endophthalmitis.
• Patients should be instructed to report any symptoms suggestive of endophthalmitis.

Use: Treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

Usual Pediatric Dose for Uveitis

12 years or older:
1 implant, containing 1 tablet of 0.59 mg of fluocinolone acetonide, to be surgically implanted into the posterior segment of the affected eye through a pars plana incision

Comments:

• Following depletion of this drug as evidenced by recurrence of uveitis, the implant may be replaced.
• Caution should be used in handling the implant to avoid damage, which may result in an increased rate of drug release from the implant.
• Care should be taken during implantation and explantation to avoid sheer forces on the implant that could disengage the silicone cup reservoir from the suture tab.
• Aseptic technique should be maintained at all times prior to and during the surgical implantation procedure.
• The implant should not be resterilized by any method.

Use: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

0.19 mg intravitreal implant: Safety and efficacy have not been established in patients younger than 18 years.

0.59 mg intravitreal implant: Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• The manufacturer product information should be consulted.

Storage requirements:

• Do not refrigerate or freeze.
• Do not open the sealed tray until just before application

Frequently asked questions

• What are the differences between Iluvien, Retisert and Yutiq intravitreal implants?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer